久久久精品区一区二区,日本精品一区99,伊人av网网

Top 10 Pharmaceutical Giants' R&D Investments in 2024 Market Trend In 2024, pharmaceutical giants face a quiet battle over innovation and efficiency. From Merck’s 41% R&D drop to AbbVie’s bold growth, their strategies and investments reveal shifting power in the industry. A glimpse into the future of drug development.
Top 16 Best-Selling New Drugs Worldwide in 2024 Market Trend Discover the top 16 best-selling new drugs of 2024, featuring innovative FIC and BIC molecules, breakthrough therapies across various fields, and products that stood out due to unique development strategies.
2024 Global CAR-T Sales Performance CAR-T Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
Top 10 Global Pharmaceutical Giants in Autoimmune Business in 2024 Autoimmune The autoimmune sector saw explosive growth in 2024, with mergers and acquisitions skyrocketing by 150%. Giants like AbbVie, J&J, and Eli Lilly are reshaping the landscape. Explore the Top 10 revenue rankings in the autoimmune business and future trends.
Novartis 2024 Q4 Financial Report Financial statements Novartis' 2024 financial report highlights strong growth with key products like Entresto, Cosentyx, and Pluvicto. The company saw a 12% revenue increase, with China market sales up 21%. Strong prospects include new treatments and strategic acquisitions.
Top 10 Immunology Drugs to Watch in 2024 AbbVie Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
November Biopharmaceutical Company Layoff Summary Layoff November 2024 saw significant layoffs in the biopharma industry, with 20 companies announcing cuts due to economic pressures, failed projects, and restructuring. Key layoffs include major firms like 23andMe, Novartis, and Bristol Myers Squibb.
Novartis 2024 Q3: Nuclear Medicine Surpasses $1 Billion, Leqvio Doubles Revenue Novartis Novartis Q3 2024 results: Revenue up 10% to $12.823B with net income soaring by 121%. Major product growth, including Entresto, Cosentyx, and Kesimpta, alongside Kisqali and Pluvicto, drive earnings. Immunology, neuroscience, and oncology sales climb as R&D and new indications expand global reach.
MNC Profiles: Who Values ??the Chinese Market Most? AstraZeneca Explore the competitive landscape of multinational pharmaceutical companies (MNCs) in China’s booming healthcare market. Delves into MNC revenue trends, strategies, and insights, highlighting which companies value the Chinese market most.
Domestic Pharma Companies 'Curve Jump' on AstraZeneca and Novartis Patents: Two Major $6 Billion Drugs' Generics Launched Ahead of Schedule Chinese Pharmaceutical Market Discover how the patent cliff for Novartis' Entresto is fueling the rise of a generic drug production chain in China. As the market braces for intense competition, early movers secure their positions while latecomers face a crowded battlefield.

< Pre 123 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水